Barry Conlan, MD
Family Medicine · Toledo, OHNPI 1568462158
Payments from drug & device makers
Across 244 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$751
- AbbVie$619
- AstraZeneca$373
- Pfizer$368
- GSK$224
- Lilly USA, LLC$222
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,05995%
- Other$2355%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $751 |
| AbbVie | 38 | $619 |
| AstraZeneca | 12 | $373 |
| Pfizer | 20 | $368 |
| GSK | 13 | $224 |
| Lilly USA, LLC | 14 | $222 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $185 |
| Baxter Healthcare | 1 | $118 |
| Welch Allyn | 1 | $118 |
| Astellas Pharma US Inc | 7 | $114 |
| Boehringer Ingelheim | 7 | $114 |
| Exact Sciences | 6 | $102 |
| Abbott | 5 | $90 |
| Axsome Therapeutics, Inc. | 4 | $88 |
| Bayer | 6 | $87 |
| Biogen | 4 | $81 |
| Amgen(2 entities) | 4 | $61 |
| Merck | 4 | $58 |
| Dexcom, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Corcept Therapeutics | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Shield Therapeutics Inc | 2 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Almatica Pharma LLC | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Novartis | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Corium, LLC | 2 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,295 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $88,902 |
| RybelsusSemaglutide | 44 | $65,523 |
| JardianceEmpagliflozin | 53 | $51,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $51,357 |
| XareltoRivaroxaban | 28 | $43,929 |
| OzempicSemaglutide | 17 | $25,259 |
| FarxigaDapagliflozin Propanediol | 34 | $21,611 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $21,486 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,680 |
| MounjaroTirzepatide | 11 | $11,394 |
| Atorvastatin Calcium | 842 | $11,087 |
| MyrbetriqMirabegron | 16 | $8,116 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,734 |
| Valsartan | 208 | $6,684 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $751 | $90,78361 claims |
| PfizerEliquis | $368 | $88,90280 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $224 | $63,17362 claims |
| Boehringer IngelheimJardiance | $114 | $51,81353 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $373 | $35,29156 claims |
| Lilly USA, LLCMounjaro | $222 | $11,39411 claims |
| Astellas Pharma US IncMyrbetriq | $114 | $8,11616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Toledo
- Henry NaddafToledo$252K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.